CMS Looks To End Pharma Co.'s Drug Classification Suit
A regulatory change in 2016 didn't require the Centers for Medicare & Medicaid Services to retroactively reclassify STI Pharma LLC's antibiotic Sulfatrim as a "non-innovator" generic that carried a lower rebate...To view the full article, register now.
Already a subscriber? Click here to view full article